Icon

While the renewals are a topic of concern for investors, analysts believe both CROs will see a re-up. (Image: iStock/shironosov)

Will Pfizer renew with Icon, Parexel? Analyst says yes

By Melissa Fassbender

This month marks the renewal period for Pfizer’s contract research organizations’ Icon and Parexel, and while revenues have been declining, analysts believe the pharma giant will renew with both companies.

Spotlight

Follow us

Featured Events

View more

Products

View more

Webinars

Featured Suppliers

All suppliers